Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GILD

1 Stock to Buy This Week Following Its Recent Earnings Beat

Biopharmaceutical giant Gilead Sciences (GILD) reported better-than-expected third-quarter earnings and sales and raised its full-year guidance. Analysts see immense growth potential in the company’s HIV and oncology franchises, which should boost its performance in the upcoming quarters. Given its strong earnings, high profitability, discounted valuation, and attractive dividend, we think…

StockNews.com

Check Out What Whales Are Doing With GILD

Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

2 No-Brainer Biotech Stocks to Buy Right Now and 1 to Sell

The biotech industry is set to benefit from continued investments in breakthrough developments and federal support. Against this backdrop, fundamentally strong biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) could be solid buys. However, Relmada Therapeutics (RLMD) might be best avoided considering its weak fundamentals. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Gilead Sciences Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

3 Biotech Stocks to Buy for Q4 and 1 to Avoid

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

StockNews.com

What Are Whales Doing With Gilead Sciences

A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 17 strange trades.

Benzinga

3 Biotech Stocks That'll Make You Richer and 1 That Won't

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns…

StockNews.com

1 Stock Under $65 That You Shouldn't Ignore

Leading biopharmaceutical company Gilead Sciences (GILD) reported impressive sales in the last quarter and raised its full-year 2022 guidance. Furthermore, the company’s strategic acquisitions, drug approvals, and research breakthroughs should drive its growth in the coming quarters. Given GILD’s discounted valuation, we think it could be wise to buy this…

StockNews.com

It's Not Too Late for Investors to Start Buying GILD Stock

Biopharmaceutical giant Gilead Sciences (GILD) has delivered solid segmental sales growth in the last reported quarter. In addition, the company’s various research breakthroughs and drug approvals should further bolster its performance in the coming months. Given its robust profitability and discounted valuation, we think it could be wise to scoop…

StockNews.com

3 Stocks to Buy Now Before They Rebound

Concerns over the potentially aggressive Fed rate hikes to tackle the elevated inflation are expected to keep the market volatile in the near term. However, fundamentally sound stocks Coca-Cola (KO), Gilead Sciences (GILD), and Packaging Corporation of America (PKG) have the potential to rebound from their current price levels. So,…

StockNews.com

5 Biotech Stocks in the Buy Zone This Week

The biotech industry is expected to see solid growth in the long term due to rising healthcare spending, breakthrough developments, and an aging population. Given the industry’s solid growth prospects and non-cyclical nature, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), Biogen (BIIB), Jazz…

StockNews.com

1 Biotech Stock Investors Will Want to Buy This Week

Gilead Sciences (GILD), a biopharmaceutical company, reported strong demand across its HIV portfolio and raised its full-year guidance. Given the company’s robust profitability and discounted valuation, we think it could be wise to buy the stock now. Read on….

StockNews.com

3 High-Yield Dividend Stocks to Buy Right Now

Amid the persisting market volatility on concerns over high inflation and a looming recession, we think it could be wise to invest in fundamentally strong dividend-paying stocks Vodafone Group (VOD), Gilead Sciences (GILD), and BHP Group (BHP) for a steady income stream. Read more….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

The 4 Best Nasdaq 100 Stocks to Buy

The Nasdaq 100 surged after the Fed announced a 75 basis-point rate hike for the second straight month and hinted at pausing the policy tightening depending on economic data. This, along with better-than-expected corporate earnings, should help the index stay resilient in the near term. Therefore, it could be wise…

StockNews.com

3 Stocks to Help You Make Passive Income in 2022

Concerns over the Fed’s aggressive interest rate hikes and growing odds of the economy sliding into a recession are expected to keep the stock market highly volatile in the upcoming months. Amid these volatile market conditions, it could be wise to invest in high dividend-yielding stocks Texas Instruments (TXN), Visa…

StockNews.com

2 Oversold Stocks Investors Will Want to Buy Before They Blast Off

The stock market sell-offs triggered by macroeconomic and geopolitical issues since the beginning of the year have driven many quality stocks into the oversold territory. So, it could be wise to invest in oversold stocks Gilead Sciences (GILD) and Comcast (CMCSA), which have solid rebound potential. Let’s discuss….

Benzinga

Gilead Sciences Whale Trades For July 14

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Gilead Is Cheapest Large-Cap Biotech Despite Some Not So Favorable Acquisitions

Even after spending over $40 billion in the past five years on acquisitions, none of the deals for Gilead Sciences Inc (NASDAQ: GILD) has delivered the blockbuster in cancer as it looked to venture away from the HIV franchise.

StockNews.com

2 Bargain Healthcare Stocks Yielding 4%

Despite the market volatility, the healthcare sector is outperforming. Thus, we think it could be wise to buy dividend-paying healthcare stocks Gilead Sciences (GILD) and Dow (DOW), which look undervalued at their current price levels. These bargain stocks are rated Buy in our proprietary rating system.

Benzinga

Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 7.45%. Currently, Gilead Sciences has a market capitalization of $74.42 billion.

StockNews.com

3 Low-Beta Stocks to Buy to Combat a Jittery Market

The Fed’s aggressive interest rate increases to tame multi-decade high inflation, and an anticipated economic slowdown, have exacerbated market volatility of late. To protect against the market uncertainties, we think investors should consider investing in low-beta stocks Merck (MRK), Gilead Sciences (GILD), and AmerisourceBergen (ABC). Let’s discuss why.

StockNews.com

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

Benzinga

Why These Analysts Are Bullish On Gilead's Q1 Earnings

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses. The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table. HIV sales,…

Benzinga

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.56% on an annualized basis producing an average annual return of 14.71%. Currently, Gilead Sciences has a market capitalization of $75.20 billion.

1 … 6 7 8 9

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.